|
 |
BenicarThis page contains recent news articles, when available, and an overview of Benicar but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Benicar (when available) Olmesartan Medoxomil, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Olmesartan Medoxomil does not have an active metabolite or possess uricosuric effects. For the treatment of hypertension Mechanism Of Action: Olmesartan Medoxomil competes with angiotensin II for binding at the also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decrease in systemic vascular resistance. News Articles on Olmesartan Medoxomil Dr. Gott: Hives may be caused by infection - Mar 28, 2009 He is currently taking Benicar, Toprol, simvastatin and a low-dose aspirin every day for cholesterol and blood pressure problems but is in good overall Northwest Herald Forest Laboratories - Mar 13, 2009 Products include Lexapro and Celexa, serotonin reuptake inhibitors for the treatment of major depression; Benicar, an angiotensin receptor blocker for the OneMedPlace CEO likes to combine science, sales - Mar 6, 2009 We combined our product Benicar, as it's known in the United States, with amlodipine, which is a different class of anti-hypertensive, into what we call a Trading Markets (press release) SDI: Novartis Regains No. 1 Position with Managed Care Pharmacy ... - 04 Feb 2009 Daiichi Sankyo’s Benicar was next with more than 70% of HMO members having access at a preferred position. Longitudinal patient data in SDI’s Vector One®: Business Wire (press release), Daiichi Sankyo May Forecast Biggest Loss by Japanese Drugmaker - Jan 27, 2009 Daiichi Sankyo generated 22 percent of sales in the latest business year from Benicar, a pill against hypertension. Takeda Pharmaceutical Co. and Astellas Bloomberg Daiichi Sankyo posts $3.7 bln Q3 loss on Ranbaxy - Jan 30, 2009 Revenues shrank 12 percent on a stronger yen and government-mandated price cuts, despite brisk sales globally of Benicar and other high-blood pressure guardian.co.uk, Forest Laboratories, Inc. Reports Q3'09 Diluted Earnings Per Share ... - Jan 20, 2009 Also included in revenues was other income of $77942000 which includes contract revenue of $47283000 from the co-promotion of Benicar(R) (olmesartan PR Newswire (press release), Waiting for Angioedema - Jan 19, 2009 He has a history of hypertension and has taken lisinopril and Benicarâ„¢ (olmesartan) for several years without recent dose titrations. EMS1.com - Emergency Medical Service Resources, '올메í…?', 아시아와 미êµì‹œìž¥ì„œ ì„ ì „ - Feb 1, 2009 2ì?¼ 미래ì—?ì…‹ì¦?권ì?´ ë°?힌 ìž?료ì—? 따르면 3분기 누계실ì ?으로 '올메í…?' 매출액ì?€ ìœ ëŸ½ì—?서만 ì „ë…„ë?™ê¸°ëŒ€ë¹„ 약 3.2% 가량 소í? ê°?소한 반면 미êµì—?ì„œ 'Benicar'ë?¼ëŠ” 메디파나뉴스, Blood pressure medicine can cause hacking cough - Dec 22, 2008 Angiotensin receptor blockers such as Avapro, Benicar, Cozaar and Diovan are less likely to cause a chronic cough. My doctors were mystified by my anemia. Los Angeles Times, Medicine triggers hallucinations - Dec 22, 2008 Angiotensin receptor blockers such as Avapro, Benicar, Cozaar and Diovan are less likely to cause a chronic cough. For more information about pros and cons Online Athens, Daiichi Sankyo Submits Application for Approval of CS-866AZ ... - Dec 11, 2008 Ltd., and the high affinity AT1 subtype angiotensin II receptor antagonist olmesartan medoxomil (Olmetec®/Benicar®), developed by DAIICHI SANKYO. PharmaLive.com (press release), High blood pressure doesn't slow Olympic swimmer - Dec 12, 2008 Today, he takes a white Benicar tablet each morning and evening. He'll probably take medication the rest of his life. He also sticks to a low-sodium diet. Austin 360, It's not the economy, stupid - Nov 19, 2008 ...vendor of patented drugs like Lexapro for depression (more than half of sales and growing), Namenda for Alzheimer's and Benicar for hypertension. Interactive Investor, Daiichi Sankyo Completes Purchase of 63.9% of Ranbaxy (Update1) - Nov 6, 2008 Daiichi Sankyo, the maker of the Benicar hypertension medicine, is mimicking Novartis AG and Johnson & Johnson in diversifying as sales of branded products Bloomberg Daiichi Sankyo Cuts Profit Forecast on Ranbaxy, R&D (Update2) - Oct 31, 2008 Sales rose 1.3 percent, led by the company's bestselling product, the high-blood-pressure pill Benicar. The Japanese company said it will include Ranbaxy's Bloomberg Daiichi Sankyo Falls Most on Record Ahead of Meeting (Update1) - Oct 7, 2008 Daiichi Sankyo, which sells the Benicar hypertension drug, and its partner Eli Lilly & Co. are awaiting US approval to sell the experimental blood thinner Bloomberg Forest Labs Sees Generic Threat - Sep 25, 2008 Principal brands include Lexapro for depression, Namenda for Alzheimer's disease, and Benicar for high blood pressure. The company turned in a very strong Trading Markets (press release), Senior Dimensions Lowers Prescription Drug Co-Payments on Many ... - Sep 24, 2008 The more widely used maintenance drugs with reduced co-pays include: Avapro and Benicar, both used to treat hypertension; Actos and Lantus, used to treat MarketWatch Zacks Analyst Blog Highlights: Forest Laboratories, Inc., CarMax ... - Sep 25, 2008 Principal brands include Lexapro for depression, Namenda for Alzheimer's disease and Benicar for high blood pressure. Forest has a number of other PR-Inside.com (Pressemitteilung), Zacks Analyst Blog Highlights: Forest Laboratories, Inc., CarMax ... - Sep 25, 2008 Principal brands include Lexapro for depression, Namenda for Alzheimer's disease and Benicar for high blood pressure. Forest has a number of other Business Wire (press release), CV Therapeutics Announces License Agreement for Ranexa(R) in ... 15 Sep 2008 ...sitagliptin (Januvia(R)), esomeprazole (Nexium(R)), fluticasone/salmeterol (Advair(R)), nebivolol (Nebilet(R)) and olmesartan (Benicar(R)).PipelineReview.com (press release), CV Therapeutics Announces License Agreement for Ranexa(R) in ... Sep 12, 2008 ...sitagliptin (Januvia(R)), esomeprazole (Nexium(R)), fluticasone/salmeterol (Advair(R)), nebivolol (Nebilet(R)) and olmesartan (Benicar(R)).Earthtimes (press release), Indian Institute Defends Conduct of Clinical Trials Aug 28, 2008 Two of the industry-sponsored trials were for Daiichi Sankyo’s Benicar (olmesartan medoxomil) and Novartis’ Diovan (valsartan), both hypertension drugs.FDA news (subscription), Drug industry jobs disappearing in NJ Aug 24, 2008 Sales for Daiichi Sankyo, which makes the blood pressure medication Benicar, increased 16 percent between 2006 and 2007 to exceed $1 billion, Salem said.New Brunswick Home News Tribune, Forest 1Q profit falls 9 percent on Azor charge - Jul 22, 2008 Revenue from Benicar, which Forest promotes with Daiichi Sankyo, came in at $52.4 million, about even with the first quarter of fiscal 2008. CNNMoney.com New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood ... - Jun 19, 2008 ...(2) Olmesartan medoxomil is marketed in the United States by Daiichi Sankyo, Inc. as Benicar(R). Benicar and Benicar HCT (olmesartan HispanicBusiness.com (press release), New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood ... - Jun 16, 2008 BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in PR Newswire (press release), Daiichi bags 2 patents for hypertension drug - Jun 16, 2008 The patents are for a key hypertension drug that sells under brand names Benicar and Benicar HCT or Olmitec and is one of its biggest money spinners Business Standard, Daiichi to pay up to $4.6 billion for control of Ranbaxy - Jun 11, 2008 Shares in Daiichi Sankyo, best known for its high blood pressure medication Benicar and the experimental blood thinner prasugrel, ended nearly 5 percent Reuters Exploring the ins and outs of blood pressure treatment - Jun 16, 2008 Two examples are Benicar and Diovan. The newest blood pressure medicine, Tekturna, has not been demonstrated to be a factor in ED, but it's so new that SouthCoastToday.com, Mesotec Moves HQ From Germany to Green Tree - Jun 6, 2008 Daiichi, based in Tokyo, has already sued Mylan over its plan to sell a copy of Benicar, claiming it would violate the 2016 patent. RedOrbit, Popular Drugs, Side-Effects and Feeling Ill - Jul 1, 2008 ...as well as the Designer Drugs; angiotensin II receptor blockers (ARBs); Olmesartan (Benicar ) including candesartan (Atacand) and irbesartan (Avapro), Rocklin and Roseville Today, Blood Pressure Medications Can Multi-Task - Jun 30, 2008 A newer group of drugs –but similar in action- came out and these “ARBsâ€? are known as Cozaar, Diovan, Avapro, Atacand and Micardis and Benicar. Best of Times, Hypertension Treatment Effective In Reversing Vascular Damage ... - Jun 22, 2008 Olmesartan medoxomil is marketed in the United States as Benicar® and in Europe as Olmetec® by Daiichi Sankyo, Inc., which funded the study. Science Daily (press release) New Study Shows BENICAR(R) (Olmesartan Medoxomil) Reverses Blood ... - Jun 16, 2008 BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in RedOrbit, Japan's Daiichi Sankyo in 4.6 bin dlr takeover of India's Ranbaxy - Jun 11, 2008 Daiichi Sankyo -- best known for its high blood pressure medication Benicar -- is seen by analysts as having a solid number of new drugs in its development AFP Drug may reverse vascular damage - Jun 18, 2008 Olmesartan medoxomil is marketed in the United States as Benicar and in Europe as Olmetec by Daiichi Sankyo Inc., which funded the study. United Press International Russian Roulette, Generic Buyout - Jun 11, 2008 Ranbaxy, one of India’s largest companies, is a leading maker of generic drugs worldwide; Daiichi is best known for its blood-pressure drug Benicar. The Week Daily Forest ends promotion of Daiichi hypertension drug - May 13, 2008 N: Quote, Profile, Research) Norvasc and Daiichi's Benicar, had won US approval in September. The companies had earlier struck a deal to co-promote Benicar. Reuters New Data Shows 45 Percent of Patients With Stage 1 Hypertension ... - May 14, 2008 Eight out of 10 (cumulative 81%) patients with stage 1 hypertension were able to reach a goal blood pressure (BP) of < 140/90 mm Hg on BENICAR and BENICAR Earthtimes (press release), Daiichi Sankyo 4th-Quarter Profit Rises on Blood Pressure Drugs - May 12, 2008 Shares of Daiichi Sankyo, which makes Benicar blood pressure pills, fell as much as 6.5 percent to 2670 yen after the earnings were announced at 1 pm They Bloomberg Pharmacopeia's First-in-Class Investigational Therapy PS433540 ... - May 16, 2008 ...(1) Prescribing Information for Coreg CR(R), Lotensin(R), Avapro(R), Benicar(R) and Norvasc(R) (2) American Heart Association news release. PR Newswire (press release), Many Possible Routes to the Goal of 120/80 - Apr 21, 2008 They include Diovan, Benicar and Avapro. Calcium channel blockers. Drugs like Norvasc, Procardia XL and DynaCirc CR help dilate blood vessels by preventing New York Times, Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter ... - Apr 15, 2008 Sales of Namenda increased 26% to $829657000 from $660295000 while the earnings contribution from the Benicar co-promotion increased 22% to $212100000 from PR Newswire (press release), Forest Labs Guides for 2009 Below Street - Apr 15, 2008 However, the company's co-promotion deal with partner Daiichi Sankyo for Benicar has expired, and there will be a gradual reduction in profit percentage on Houston Chronicle, Forest Lab Swings To Profit In Q4; Sees FY09 Results Below Street ... - Apr 15, 2008 The company also predicts nearly 4% revenue growth for the year that includes product sales as well as the earnings contribution from Benicar, RTT News, Forest backs pipeline as Lexapro and Namenda climb again - Apr 16, 2008 The antihypertensive Benicar (olmesartan medoxomil), which is co-promoted with Japan’s Daiichi Sankyo, brought in $58.2 million, an increase of 27%. Pharma Times (subscription), Posted By Dr. Peter Gott - Apr 7, 2008 He is on Zetia, Benicar, Lipitor, aspirin and Effexor. His problem is that when he lies on his left side, he hears a pulsating blood-flow noise in his right Northern Daily News, Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter ... - Apr 15, 2008 ...earnings contribution of $58232000 from the co-promotion of Benicar(R) (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies, Biloxi Sun Herald, Forest Laboratories, Inc. Announces Amendment to Bystolic(TM ... - Feb 28, 2008 Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered FOXBusiness Daiichi Sankyo Gains After Drug Gets Priority Review (Update6) - Feb 21, 2008 Daiichi jumped 4.2 percent as the Tokyo-based company moved closer to its first US release of an original drug since the Benicar blood-pressure pill in 2002 Bloomberg Forest Laboratories, Inc. Announces Positive Results of Memantine ... - Feb 5, 2008 ...*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered FOXBusiness Under the Weather - Jan 31, 2008 Successful drugs include Benicar, a small-selling cholesterol drug called Welchol and a new blood pressure pill called Azor. And now comes perhaps the Forbes, Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share ... - Jan 15, 2008 Namenda sales exceeded $200 million for the first time, while Lexapro also generated record sales and income from the Benicar(R) co-promotion remained CNNMoney.com Daiichi Sankyo Profit Triples on Sales of Blood Pressure Drugs - Jan 30, 2008 ...or 107 yen a share, a year earlier, the maker of the Benicar hypertension medicine said in a statement to the Tokyo Stock Exchange. Bloomberg Daiichi Sankyo Profit Rises on Blood Pressure Drugs (Update1) - Jan 30, 2008 31, from 77.7 billion yen, or 107 yen, a year earlier, the maker of the Benicar hypertension medicine said in a statement to the Tokyo Stock Exchange today. Bloomberg Forest Raises 2008 Profit Outlook - Jan 15, 2008 Forest also said it will complete its co-promotion deal for the high blood pressure drug Benicar at the end of the fiscal year and will reallocate the sales Houston Chronicle, Forest Laboratories 3Q net rises; Lexapro sales up - Jan 15, 2008 ...from $250.3 million, or 78 cents a share, a year earlier, helped in part by the co-promotion of antihypertensive therapies Benicar and Benicar HCT. MarketWatch Lexapro, Namenda Boost Outlook for Forest Labs - Jan 15, 2008 Sales of antihypertensive therapies Benicar and Benicar HCT, which it co-promotes with Japanese company Daiichi Sankyo Co. Ltd., grew 34% to $830.4 million. Wall Street Journal Forest Labs Q3 Profit Up 21% On Strong Sales Of Lexapro And ... - Jan 15, 2008 Also included in the revenues were earnings contribution of $51.8 million from the co-promotion of Benicar and Benicar HCT, antihypertensive therapies, RTT News, Novexel and Forest Laboratories Announce License Agreement for NXL ... - Jan 22, 2008 ...*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered CNNMoney.com Forest Labs 3Q Profit Up 20.6 Percent - Jan 15, 2008 Other income, which includes contract revenue from the high blood pressure drugs Benicar and Benicare HCT, totaled $80.1 million. Houston Chronicle, Forest Labs profit rises due to depression and Alzheimer's drugs - Jan 15, 2008 Other products include Benicar and Campral. Benicar is used in the treatment of hypertension. Campral is for the maintenance of abstinence from alcohol in Pravda, Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share ... - Jan 15, 2008 ...earnings contribution of $51753000 from the co-promotion of Benicar(R)* (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies, Biloxi Sun Herald, Forest Laboratories: Share price displays bullish "flag" formation - Jan 23, 2008 Offerings include Lexapro, for the treatment of depression, Namenda for Alzheimer's disease, Benicar for hypertension, and Campral for the maintenance of BloggingStocks Lexapro and Namenda help Forest beat analyst estimates - Jan 16, 2008 The antihypertensive Benicar (olmesartan medoxomil), which is co-promoted with Japan’s Daiichi Sankyo, brought in $51.8 million, an increase of 34%. Pharma Times (subscription), WRAPUP 1-Takeda and Daiichi profits up, Chugai shares tank - Jan 31, 2008 ...formed when Sankyo bought Daiichi Pharmaceutical, posted a stronger climb in income on a jump in sales for its high blood pressure medicine Benicar. Reuters UK, Takeda 9mth profit up 25 pct on strong Actos sales - Jan 30, 2008 ...profit for the April-December period jumped, rising 24 percent to 96.4 billion yen, helped by strong sales of its high blood pressure medicine Benicar. Guardian Unlimited, Forest's Third-Quarter Profit Increases on Drug Sales (Update4) - Jan 15, 2008 Revenue from the blood-pressure drug Benicar, which Forest co- promotes with Japan's Daiichi Sankyo Co., increased 34 percent to $51.8 million. Bloomberg The Street Corner: Global Market Perspective vs. Forest ... - Feb 5, 2008 In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. products Benicar, an angiotensin receptor blocker; Benicar HCT, Trading Markets (press release), Brand Names/Synonyms: Benicar is also known by the following brand names and/or synonymsBenicar; CS 866; Olmesartan; Olmesartan Medoximil; Olmesartan Medoxomil; Olmetec Drug Category: Benicar is categorized under the following by the FDA: Antihypertensive Agents; ATC:C09CA08 Dosage Forms: ~13 hours Absorption: Bioavailability is about 26% Interactions: Drug Interactions for Olmesartan Medoxomil: No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH)3/Mg(OH)2]. Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce or are metabolized by those enzymes are not expected. Chemical IUPAC Name: (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-imidazole-4-carboxylate : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |